MedTrace Logo

Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)

NCT00390767 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-03-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and activity of increasing doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with peripheral arterial disease.

Conditions

  • PAD
  • Claudication

Interventions

BIOLOGICAL

MultiGeneAngio

Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially

Sponsors & Collaborators

  • MultiGene Vascular Systems Ltd.

    lead INDUSTRY

Principal Investigators

  • Sam L Teichman, MD · Independent consultant

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00390767 on ClinicalTrials.gov